Search Result

Results for "

necroptosis inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Necroptosis (21) 11β-HSD (1) Apoptosis (12) Atg8/LC3 (2) Autophagy (7) Btk (1) DNA/RNA Synthesis (1) ERK (2) Ferroptosis (2) Fungal (2) HDAC (1) Histone Methyltransferase (2) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Keap1-Nrf2 (1) Mixed Lineage Kinase (10) p62 (2) PAK (1) PI3K (3) Reactive Oxygen Species (2) RIP kinase (28) TNF Receptor (3) VEGFR (2)
By Research Areas:	Cancer (33) Cardiovascular Disease (4) Infection (2) Inflammation/Immunology (19) Metabolic Disease (1) Neurological Disease (8)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Necroptosis

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135826

Necroptosis-IN-1	RIP kinase Necroptosis	Cancer
Necroptosis-IN-1, an analog of Necrostatin-1, is a potent *necroptosis* inhibitor. Necroptosis-IN-1 is a RIPK inhibitor .

HY-148454

Necroptosis-IN-3	Necroptosis 11β-HSD	Inflammation/Immunology Cancer
Necroptosis-IN-3 (Compound 69) is a *necroptosis* inhibitor that inhibits TNF-α induced necroptosis . Necroptosis-IN-3 (Compound STX1638) also inhibits 11β-HSD1 .

HY-14622

Necrostatin 2 5+ Cited Publications	RIP kinase	Cancer
Necrostatin 2 is a potent *necroptosis* inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

HY-N3417

Kongensin A 1 Publications Verification	HSP RIP kinase Apoptosis Necroptosis	Inflammation/Immunology Cancer
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent HSP90 inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent *necroptosis* inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-122909

GSK2593074A 1 Publications Verification GSK'074	RIP kinase	Inflammation/Immunology
GSK2593074A (GSK’074) is a *necroptosis* inhibitor with dual targeting ability to both RIP1 and RIP3 .

HY-161843

Necroptosis-IN-4	Necroptosis RIP kinase	Inflammation/Immunology
Necroptosis-IN-4, a potent *necroptosis* inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α .

HY-161911

Necroptosis-IN-5	Necroptosis RIP kinase	Neurological Disease Inflammation/Immunology Cancer
Necroptosis-IN-5 (Compound 26) is an orally active *necroptosis* inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers .

HY-162348

Antitumor agent-145	Necroptosis	Cancer
Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing *necroptosis* and activating the necroptosis-related immune response .

HY-148767

MLKL-IN-5	Mixed Lineage Kinase	Others
MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .

HY-156368

RIPK3-IN-4	RIP kinase	Inflammation/Immunology
RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, *necroptosis* and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .

HY-169023

Antiangiogenic agent 6	Apoptosis	Cancer
Antiangiogenic agent 6 (Pt-1) can inhibit angiogenesis. Antiangiogenic agent 6 can induce necroptosis in tumor cells .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-161361

MLKL-IN-7	Mixed Lineage Kinase	Cancer
MLKL-IN-7 (compound 9) is a MLKL inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC₅₀ of 148.4 nM .

HY-103028A

GSK963 1 Publications Verification	RIP kinase	Others
GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC₅₀ of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro .

HY-117200

Necrostatin-7 Nec-7	Necroptosis	Cancer
Necrotatin-7 (Nec-7) is a potent *necroptosis* inhibitor with an EC₅₀ of 10.6 μM. Necrotatin-7 does not inhibit recombinant RIP1 kinase .

HY-111838

ZZW-115	Apoptosis	Cancer
ZZW-115 is a potent NUPR1 inhibitor, with a K_d of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. Anticancer activity .

HY-111838A

ZZW-115 hydrochloride 3 Publications Verification	Apoptosis	Cancer
ZZW-115 hydrochloride is a potent NUPR1 inhibitor, with a K_d of 2.1 μM. ZZW-115 hydrochloride induces tumor cell death by necroptosis and apoptosis. Anticancer activity .

HY-121954

Necrostatin-1 (inactive control) Nec-1 (inactive control)	Others	Cancer
Necrostatin-1 (Nec-1) (inactive control) is an inactive analog of Necrostatin-1 (HY-15760). Necrostatin-1 is a potent necroptosis inhibitor .

HY-144277

RIPK1-IN-12	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC₅₀ values of 1.6 and 2.9 nM, respectively .

HY-157039

RIPK1-IN-17	RIP kinase	Inflammation/Immunology
RIPK1/3-IN-17 (Compound 10) is a RIPK1 and RIPK3 inhibitor. RIPK1/3-IN-17 specifically inhibits necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation .

HY-124546

Necrostatin-5 Nec-5	Necroptosis RIP kinase	Neurological Disease
Necrostatin-5 (Nec-5) is a potent *necroptosis* inhibitor with an EC₅₀ value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects .

HY-14909

Bardoxolone 10+ Cited Publications CDDO; RTA 401	Keap1-Nrf2 Necroptosis	Metabolic Disease Cancer
Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent *necroptosis* inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .

HY-110111

T2AA	DNA/RNA Synthesis	Cancer
T2AA is a monoubiquitinated proliferating cell nuclear antigen (PCNA) inhibitor that prevents DNA repair, increases double-strand break (DSB) formation and promotes necroptosis and cell cycle arrest in G1 phase .

HY-15760

Necrostatin-1 Maximum Cited Publications 297 Publications Verification Nec-1	RIP kinase Autophagy Indoleamine 2,3-Dioxygenase (IDO) Ferroptosis	Cancer
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC₅₀ of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC₅₀=182 nM). Necrostatin-1 is also an IDO inhibitor .

HY-146758

RIPK1-IN-14	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC₅₀ value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells .

HY-158312

UH15-38	Necroptosis RIP kinase Influenza Virus	Infection Inflammation/Immunology
UH15-38 is a potent RIPK3 inhibitor with an IC₅₀ value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated *necroptosis*. UH15-38 dampens IAV-induced lung injury .

HY-161059

ZB-R-55	RIP kinase	Infection
ZB-R-55 is an orally active RIPK1 inhibitor. ZB-R-55 can be used for sepsis study .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits *necroptosis* by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-144276

RIPK1-IN-11	RIP kinase	Inflammation/Immunology
RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (K_d=9.2 nM; IC₅₀=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC₅₀=17-30 nM). Anti-inflammatory activity .

HY-162046

Anticancer agent 178	Necroptosis Ferroptosis	Cancer
Anticancer agent 178 (compound C2) is a potent anticancer agent. Anticancer agent 178 inhibits MDA-MB 231 cells proliferation and metabolic activity with IC₅₀s of 1.1 and 4.2 μM. Anticancer agent 178 induces ferroptosis and *necroptosis* in cells .

HY-159589

BTK-IN-37	Btk Apoptosis	Cancer
BTK-IN-37 (compound 8d) is a BTK inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with K_i and IC₅₀ of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .

HY-163390

RIP1 kinase inhibitor 9	RIP kinase Necroptosis	Inflammation/Immunology Cancer
RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced *necroptosis* in HT-29 cells with an EC₅₀ of 7.04 nM .

HY-156367

RIPK1-IN-16	RIP kinase	Inflammation/Immunology
RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .

HY-146757

RIPK1-IN-13	RIP kinase	Inflammation/Immunology
RIPK1-IN-13 (Compound 8) is a potent inhibitor of RIPK1 with an IC₅₀ value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases .

HY-112292

GW806742X 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Others
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against VEGFR2 (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis .

HY-N0244

Theaflavin-3'-gallate 1 Publications Verification	Apoptosis Necroptosis	Cancer
Theaflavin-3'-gallate is a monomer of theaflavins found in black tea, which has anti-UVB damage activity and inhibits cell apoptosis and *necroptosis. Theaflavin-3'-gallate acts as a pro-oxidant and induces oxidative stress in cancer cells, inhibiting* xanthine oxidase (OX), with an IC₅₀ of 7.6 μM .

HY-112292A

GW806742X hydrochloride 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Cancer
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis .

HY-100573

Necrosulfonamide 80+ Cited Publications	Mixed Lineage Kinase	Cancer
Necrosulfonamide is a *necroptosis* inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .

HY-101872

GSK-872 60+ Cited Publications	RIP kinase	Inflammation/Immunology
GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .

HY-101872A

GSK-872 hydrochloride 60+ Cited Publications	RIP kinase	Inflammation/Immunology
GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .

HY-120600

Sibiriline	Necroptosis Apoptosis RIP kinase	Inflammation/Immunology
Sibiriline is a specific competitive inhibitor of RIPK1 that targets the RIPK1 ATP-binding site and locks it in an inactive conformation. Sibiriline inhibits TNF-induced RIPK1-dependent necroptosis and RIPK1-dependent apoptosis, but does not protect cells from caspase-dependent apoptosis. Sibiriline protects mice from concanavalin A-induced hepatitis and has the potential to inhibit immune-dependent hepatitis. .

HY-151541

MLKL-IN-3	Mixed Lineage Kinase Necroptosis	Neurological Disease
MLKL-IN-3 (compound 66) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits *necroptosis* in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 31 nM . MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151542

MLKL-IN-4	Mixed Lineage Kinase Necroptosis RIP kinase	Neurological Disease
MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits *necroptosis* in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM . MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155179

ZMF-23	PAK HDAC	Cancer
ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated *necroptosis, and further enhances apoptosis. ZMF-23 inhibits* the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC) .

HY-100573S

Necrosulfonamide-d4	Mixed Lineage Kinase	Cancer
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

HY-135953

CDDO-3P-Im	Apoptosis	Cancer
CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model . CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R) .

HY-100573A

(E/Z)-Necrosulfonamide	Mixed Lineage Kinase	Cancer
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a *necroptosis* inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

HY-162928

RIPK1-IN-26	RIP kinase	Neurological Disease
RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders .

HY-168770

Cl-Necrostatin-1	RIP kinase TNF Receptor Apoptosis	Cardiovascular Disease
Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC₅₀ = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases .

Cat. No.	Product Name

HY-L133

Cuproptosis Compound Library

240 compounds

Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".

The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.

Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.

Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.

MCE supplies a unique collection of 240 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cat. No.	Product Name	Target	Research Area